X
Xiaodong Shen
Researcher at Genentech
Publications - 22
Citations - 3775
Xiaodong Shen is an academic researcher from Genentech. The author has contributed to research in topics: Atezolizumab & Population. The author has an hindex of 11, co-authored 21 publications receiving 2991 citations.
Papers
More filters
Journal ArticleDOI
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles,Joseph Paul Eder,Gregg Fine,Fadi Braiteh,Yohann Loriot,Cristina Cruz,Joaquim Bellmunt,Howard A. Burris,Daniel P. Petrylak,Siew-leng Melinda Teng,Xiaodong Shen,Zachary Boyd,Priti S. Hegde,Daniel S. Chen,Nicholas J. Vogelzang +14 more
TL;DR: It is demonstrated that tumours expressing PD-L1-positive tumour-infiltrating immune cells had particularly high response rates, and patients with UBC, who are often older and have a higher incidence of renal impairment, may be better able to tolerate MPDL3280A versus chemotherapy.
Journal ArticleDOI
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Thomas Powles,Ignacio Duran,Michiel S. van der Heijden,Yohann Loriot,Nicholas J. Vogelzang,Ugo De Giorgi,Stéphane Oudard,Margitta Retz,Daniel Castellano,Aristotelis Bamias,Aude Flechon,Gwenaelle Gravis,Syed A. Hussain,Toshimi Takano,Ning Leng,Edward E. Kadel,Romain Banchereau,Priti S. Hegde,Sanjeev Mariathasan,Na Cui,Xiaodong Shen,Christina Louise Derleth,Marjorie C. Green,Alain Ravaud +23 more
TL;DR: Atezolizumab was not associated with significantly longer overall survival than chemotherapy in patients with platinum-refractory metastatic urothelial carcinoma overexpressing PD-L1, thus precluding further formal statistical analysis.
Journal ArticleDOI
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Thomas Powles,Zoe June Assaf,Nicole N. Davarpanah,Romain Banchereau,Bernadett Szabados,Kobe C. Yuen,Petros Grivas,Petros Grivas,Petros Grivas,Maha Hussain,Stéphane Oudard,Jürgen E. Gschwend,Peter Albers,Daniel Castellano,Hiroyuki Nishiyama,Siamak Daneshmand,Shruti Sharma,Bernhard Zimmermann,Himanshu Sethi,Alexey Aleshin,Maurizio Perdicchio,Jingbin Zhang,David S. Shames,Viraj Degaonkar,Xiaodong Shen,Corey Carter,Carlos Bais,Joaquim Bellmunt,Sanjeev Mariathasan +28 more
TL;DR: In this paper, the authors evaluated outcomes in 581 patients who had undergone surgery and were evaluable for ctDNA from a randomized phase III trial of adjuvant atezolizumab versus observation in operable urothelial cancer.
Journal ArticleDOI
Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).
Thomas Powles,Nicholas J. Vogelzang,Gregg Fine,Joseph Paul Eder,Fadi Braiteh,Yohann Loriot,Cristina Cruz Zambrano,Joaquim Bellmunt,Howard A. Burris,Siew-leng Melinda Teng,Xiaodong Shen,Hartmut Koeppen,Priti S. Hegde,Daniel S. Chen,Daniel P. Petrylak +14 more
TL;DR: PD-L1 expression is prevalent in this disease and may protect cancer cells from immune-mediated degranulation, leading to a poor prognosis and limited treatment options.
Journal ArticleDOI
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
David R. Spigel,Scott N. Gettinger,Leora Horn,Roy S. Herbst,Leena Gandhi,Michael S. Gordon,Cristina Cruz,Paul Conkling,Philippe A. Cassier,Scott J. Antonia,Howard A. Burris,Gregg Fine,Ahmad Mokatrin,Marcin Kowanetz,Xiaodong Shen,Daniel S. Chen,Jean-Charles Soria +16 more
TL;DR: MPDL3280A, a human monoclonal Ab containing an engineered Fc-domain designed to inhibit anti-cancer immune responses, is introduced into the clinic for the treatment of lung cancer.